Introduction
============

Inositol 1,4,5-trisphosphate receptors (IP~3~R) are intracellular Ca^2+^ channels expressed in the membranes of the endoplasmic reticulum (ER) in most eukaryotic cells (Berridge, [@b3]; Taylor *et al*., [@b70]; Foskett *et al*., [@b19]; nomenclature follows Alexander *et al*., [@b1]). IP~3~Rs are essential links between the many extracellular signals that stimulate PLC and initiation of cytosolic Ca^2+^ signals triggered by IP~3~-evoked Ca^2+^ release from the ER. Three genes encode closely related IP~3~R subunits in vertebrates, whereas invertebrates have only a single IP~3~R gene (Taylor *et al*., [@b70]). Each of the three vertebrate IP~3~R subtypes encodes a large polypeptide of about 2700 residues, and they share about 70% amino acid sequence identity (Foskett *et al*., [@b19]). Within each IP~3~R subunit, IP~3~ binds to a clam-like IP~3~-binding core (IBC; residues 224--604 in IP~3~R1) (Bosanac *et al*., [@b10]) near the N-terminus. IP~3~ binding to the IBC re-orients its relationship with the associated suppressor domain (residues 1--223). That rearrangement disrupts interactions between adjacent subunits within the tetrameric IP~3~R leading to gating of the Ca^2+^-permeable channel (Seo *et al*., [@b61]). This central channel of each tetrameric IP~3~R is formed by transmembrane helices and their associated re-entrant loops. These pore-forming structures lie towards the C-terminal of each subunit. How IP~3~-evoked re-arrangement of N-terminal domains of the IP~3~R leads to opening of the pore is not yet resolved, although it is likely to be conserved in all IP~3~R subtypes and broadly similar for the other major family of intracellular Ca^2+^ channels, ryanodine receptors (Seo *et al*., [@b61]).

Most cells express mixtures of IP~3~R subtypes, although tissues differ in which complements of IP~3~R subunits they express (Taylor *et al*., [@b70]). Furthermore, the subunits assemble into both homo-tetrameric and hetero-tetrameric structures (Wojcikiewicz and He, [@b79]). Although all IP~3~Rs are built to a common plan and they are all regulated by IP~3~ and Ca^2+^ (Foskett *et al*., [@b19]; Seo *et al*., [@b61]), the subtypes are subject to different modulatory influences (Patterson *et al*., [@b51]; Higo *et al*., [@b29]; Foskett *et al*., [@b19]; Betzenhauser *et al*., [@b5]; Wagner and Yule, [@b75]) and they are likely to fulfil different physiological roles (Matsumoto *et al*., [@b39]; Hattori *et al*., [@b27]; Futatsugi *et al*., [@b20]; Tovey *et al*., [@b72]; Wei *et al*., [@b76]). It is, however, difficult to disentangle the physiological roles of IP~3~R subtypes in cells that typically express complex mixtures of homo- and hetero-tetrameric IP~3~Rs. There are no ligands of IP~3~Rs that usefully distinguish among IP~3~R subtypes (Saleem *et al*., [@b58]; [@b59]) and nor are there effective antagonists that lack serious side effects (Michelangeli *et al*., [@b41]). Heparin (Ghosh *et al*., [@b22]), caffeine (Parker and Ivorra, [@b50]), 2-aminoethoxydiphenyl borate (2-APB) (Maruyama *et al*., [@b38]) and Xestospongins (Gafni *et al*., [@b21]) have all been widely used to inhibit IP~3~-evoked Ca^2+^ release, but each has its limitations (see Results). Furthermore, the interactions of these antagonists with IP~3~R subtypes have not been assessed. Peptides derived from myosin light-chain kinase (Nadif Kasri *et al*., [@b45]; Sun and Taylor, [@b66]), the N-terminal of IP~3~R1 (Sun *et al*., [@b67]) or the BH4 domain of bcl-2 (Monaco *et al*., [@b44]) also inhibit IP~3~-evoked Ca^2+^ release. These peptides are unlikely to provide routes to useful IP~3~R antagonists because they are effective only at high concentrations and they need to be made membrane-permeable. A naturally occurring protein that inhibits IP~3~ binding to IP~3~R, IRBIT (Ando *et al*., [@b2]), has the same limitations as an experimental tool, and it is effective only when phosphorylated. Many other drugs inhibit IP~3~-evoked Ca^2+^ release, but none of these has found widespread use (see Michelangeli *et al*., [@b41]; Bultynck *et al*., [@b12]).

In the present study, we provide the first systematic analysis of the interactions between IP~3~R subtypes and each of the commonly used antagonists. We use DT40 cell lines stably expressing only a single mammalian IP~3~R subtype to define the effects of these antagonists on IP~3~-evoked Ca^2+^ release via each IP~3~R subtype.

Methods
=======

Measurement of IP~3~-evoked Ca^2+^ release
------------------------------------------

We used DT40 cells lacking endogenous IP~3~Rs (Sugawara *et al*., [@b65]), but stably expressing rat IP~3~R1 (GenBank accession number GQ233032.1; Pantazaka and Taylor, [@b49]), mouse IP~3~R2 (GU980658.1; Tovey *et al*., [@b73]) or rat IP~3~R3 (GQ233031.1; Rahman *et al*., [@b52]). Cells were grown in suspension in RPMI 1640 medium supplemented with 10% FBS, 1% heat-inactivated chicken serum, 2 mM glutamine and 50 μM 2-mercaptoethanol at 37°C in humidified air containing 5% CO~2~. Cells were used or passaged when they reached a density of ∼1.5 × 10^6^ cells mL^−1^.

A low-affinity Ca^2+^ indicator trapped within the ER of permeabilized DT40 cells was used to measure IP~3~-evoked Ca^2+^ release (Tovey *et al*., [@b71]; Saleem *et al*., [@b58]). Briefly, the ER was loaded with indicator by incubating cells (∼5 × 10^7^ mL^−1^) in the dark with Mag-fluo-4AM (20 μM) in HEPES-buffered saline (HBS) containing 0.02% (v/v) Pluronic F127 for 1 h at 22°C. HBS had the following composition: 135 mM NaCl, 5.9 mM KCl, 11.6 mM HEPES, 1.5 mM CaCl~2~, 11.5 mM glucose, 1.2 mM MgCl~2~, pH 7.3. After permeabilization of the plasma membrane with saponin (10 μg·mL^−1^, 4 min, 37°C) in Ca^2+^-free cytosol-like medium (CLM), permeabilized cells were washed (650× *g*, 2 min) and resuspended (∼10^7^ mL^−1^) in Mg^2+^-free CLM containing carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 10 μM) to inhibit mitochondria, and supplemented with CaCl~2~ to give a final free \[Ca^2+^\] of 220 nM after addition of 1.5 mM MgATP. Ca^2+^-free CLM had the following composition: 2 mM NaCl, 140 mM KCl, 1 mM EGTA, 20 mM PIPES, 2 mM MgCl~2~, pH 7.0. Permeabilized cells were then distributed into 96-well plates (50 μL, 5 × 10^5^ cells per well), centrifuged (300× *g*, 2 min) and used for experiments at 20°C. Addition of MgATP (1.5 mM) allowed Ca^2+^ uptake by the ER, which was monitored at intervals of ∼1 s using a FlexStation-3 plate reader (MDS Analytical Devices, Berkshire, UK; Tovey *et al*., [@b71]). After 2 min, when the ER had loaded to steady-state with Ca^2+^, IP~3~ was added with CPA (10 μM) to inhibit further Ca^2+^ uptake. IP~3~-evoked Ca^2+^ release was expressed as a fraction of that released by ionomycin (1 μM; Tovey *et al*., [@b71]). Similar methods were used to measure IP~3~-evoked Ca^2+^ release from intact or permeabilized HEK cells (Tovey *et al*., [@b72]). The timings of antagonist additions are described in the figure legends. The affinity of each competitive antagonist (pK~D~) was determined from the intercept on the abscissa of the Schild plot.

Concentration--effect relationships were fitted to Hill equations using Prism (version 5.0, GraphPad, San Diego, CA, USA), from which Hill coefficients (*h*), the fraction of the intracellular Ca^2+^ stores released by a maximally effective concentrations of IP~3~, and pEC~50~ values were calculated.

Expression of N-terminal fragments of IP~3~ receptors
-----------------------------------------------------

The plasmids used for bacterial expression of GST-tagged N-terminal fragments (NT, residues 1--604) of rat IP~3~R1, mouse IP~3~R2 and rat IP~3~R3 have been described, and their coding sequences have been confirmed (Khan *et al*., [@b32]). Plasmids were transformed into BL21-CodonPlus (DE3)-RILP competent cells (Rossi and Taylor, [@b54]), and grown for 12 h at 37°C in 20 mL of Luria-Bertani (LB) medium containing carbecillin (50 μg·mL^−1^). The volume of medium was then increased to 1 L, and the incubation was continued at 37°C for 3--4 h until the OD~600~ reached 1--1.5. Protein expression was induced by addition of IPTG (0.5 mM) for 20 h at 15°C. Bacteria were harvested (6000× *g*, 5 min), washed twice with cold PBS, and the pellet was suspended (∼10^9^ cells·mL^−1^) in 50 mL of Tris-EDTA medium (TEM: 50 mM Tris, 1 mM EDTA, pH 8.3) supplemented with 10% PopCulture, 1 mM 2-mercaptoethanol and protease inhibitor cocktail (Roche, Burgess Hill, West Sussex, UK; 1 tablet per 50 mL). After lysis by incubation with lysozyme (100 μg·mL^−1^) and RNAse (10 μg·mL^−1^) for 30 min on ice and then sonication (Transsonic T420 water bath sonicator, Camlab, Cambridge, UK; sonicator, 50 Hz, 30 s), the supernatant was recovered (30,000× *g*, 60 min, 4°C). The supernatant was mixed with glutathione Sepharose 4B beads (50:1, v/v, lysate : beads) and incubated with gentle end-over-end rotation (6 rpm) for 45 min at 4°C. The beads were then loaded onto a PD-10 column and washed twice with PBS and twice with PreScission cleavage buffer (GE Healthcare) supplemented with 1 mM DTT. The column was then incubated with 0.5 mL of PreScission cleavage buffer containing 1 mM DTT and 80 units of GST-tagged PreScission protease for 12 h at 4°C using gentle end-over-end rotation. The PreScission protease cuts an engineered cleavage site to release the NT free of its GST tag. The eluted NT (∼15 mg protein mL^−1^) was rapidly frozen and stored at −80°C.

^3^H-IP~3~ binding
------------------

Equilibrium competition binding assays were performed at 4°C in 500 μL of CLM (final free \[Ca^2+^\] = 220 nM) containing purified NT (30 μg) or cerebellar membranes (5 mg protein), ^3^H-IP~3~ (1.5 nM) and appropriate concentrations of competing ligand. Reactions were terminated after 5 min by centrifugation (20,000× *g*, 5 min) for membranes, or by centrifugation after addition of poly(ethylene glycol)-8000 \[30% (w/v), 500 μL\] and γ-globulin (30 μL, 25 mg·mL^−1^) for NT. The pellet was washed (500 μL of 15% PEG or CLM) and solubilized in 200 μL of CLM containing 1% (v/v) Triton-X-100 before liquid scintillation counting. Non-specific binding, whether determined by addition of 10 μM IP~3~ or by extrapolation of competition curves to infinite IP~3~ concentration, was \<10% of total binding. Results were fitted to Hill equations using Prism, from which IC~50~ values were calculated. K~D~ (equilibrium dissociation constant) and pK~D~ (--logK~D~) values were calculated from IC~50~ values using the Cheng and Prusoff equation (Cheng and Prusoff, [@b14]).

Data analysis
-------------

Statistical comparisons used pEC~50~ (or pK~D~) values. For paired comparison of the effect of an antagonist, ΔpEC~50~ values were calculated, where ΔpEC~50~ = . Results are expressed as means ± SEM from *n* independent experiments. Statistical comparisons used paired Student\'s *t*-test or [anova]{.smallcaps} followed by Bonferroni\'s test, with *P* \< 0.05 considered significant.

Materials
---------

Sources of many reagents were specified in earlier publications (Rossi *et al*., [@b56],[@b57]; Saleem *et al*., [@b58]). IP~3~ was from Enzo Life Sciences (Exeter, UK). ^3^H-IP~3~ (19.3 Ci mmol^−1^) was from PerkinElmer (Buckinghamshire, UK). Heparin (from porcine mucosa, M~r~ 5000) and cyclopiazonic acid (CPA) were from Fisher Scientific (Loughborough, UK). Caffeine, 2-APB, lysozyme, RNAse, γ-globulin and poly(ethylene glycol)-8000 were from Sigma-Aldrich (Dorset, UK). Xestopongins C and D were from Calbiochem (Gibbstown, NJ, USA) or isolated and characterized as previously described (Gafni *et al*., [@b21]). PopCulture was from Novagen (Darmstadt, Germany). Simply Blue stain was from Invitrogen (Renfrewshire, Scotland). Dioxin-free isopropyl-β-D-thiogalactoside (IPTG), and Luria--Bertani agar and broth were from Formedium (Norfolk, UK). Glutathione Sepharose 4B beads and GST-tagged PreScission protease were from GE Healthcare (Buckinghamshire, UK). Carbecillin was from Melford Laboratories (Suffolk, UK). BL21-CodonPlus (DE3)-RILP competent bacteria were from Agilent Technology (Berkshire, UK).

Results
=======

Heparin is a competitive antagonist with different affinities for IP~3~ receptor subtypes
-----------------------------------------------------------------------------------------

Heparin is a competitive antagonist of IP~3~-evoked Ca^2+^ release (Ghosh *et al*., [@b22]), but it is membrane-impermeable and it has many additional effects. These include uncoupling of receptors from G-proteins (Willuweit and Aktories, [@b77]; Dasso and Taylor, [@b15]), stimulation of ryanodine receptors (Ehrlich *et al*., [@b18]) and inhibition of IP~3~ 3-kinase (Guillemette *et al*., [@b26]). To assess the effects of heparin on each IP~3~R subtype, permeabilized DT40 cells expressing each of the three IP~3~R subtypes were incubated with heparin for 35 s. The effect of IP~3~ on Ca^2+^ release from the intracellular stores was then assessed (Figure [1](#fig01){ref-type="fig"}A). In permeabilized DT40-IP~3~R1 cells, heparin caused parallel rightward shifts of the concentration--response relationship for IP~3~-evoked Ca^2+^ release (Figure [1](#fig01){ref-type="fig"}B). Schild plots, which had slopes of 0.95 ± 0.02 (mean ± SEM, *n* = 3), established that the equilibrium dissociation constant (K~D~) for heparin was 4.1 μg·mL^−1^ (pK~D~ = 5.39 ± 0.00) (Figure [1](#fig01){ref-type="fig"}C). Similar results were obtained when adenophostin A (AdA), a high-affinity agonist of IP~3~Rs (Rossi *et al*., [@b57]; Saleem *et al*., [@b59]), was used to stimulate Ca^2+^ release. The Schild plots had slopes of 0.94 ± 0.03 (*n* = 3) and the K~D~ for heparin was 6.9 μg·mL^−1^ (pK~D~ = 5.16 ± 0.05) (Figure [1](#fig01){ref-type="fig"}D and E; Table [1](#tbl1){ref-type="table"}).

![Heparin competitively inhibits IP~3~-evoked Ca^2+^ release via type 1 IP~3~ receptors. (A) Typical traces from a population of permeabilized DT40-IP~3~R1 cells showing the fluorescence (RFU, relative fluorescence units) recorded from a luminal Ca^2+^ indicator after addition of MgATP (1.5 mM), heparin (400 μg·mL^−1^, red lines; or CLM alone, black lines) and then IP~3~ (1 or 100 μM). The traces show average responses from two wells in a single plate. (B) Experiments similar to those in A show concentration-dependent effects of IP~3~ on Ca^2+^ release in the presence of the indicated concentrations of heparin. (C) Schild analysis of the results shown in B. (D, E) Similar analyses of the effects of heparin on AdA-evoked Ca^2+^ release via IP~3~R1. Results (B--E) are means ± SEM from three experiments.](bph0171-3298-f1){#fig01}

###### 

Effects of heparin on IP~3~-evoked Ca^2+^ release and IP~3~ binding

                    Functional analysis   [a](#tf1-1){ref-type="table-fn"}Binding   pEC~50~(IP~3~)-pK~D~(heparin)   
  --------- ------- --------------------- ----------------------------------------- ------------------------------- ----------------------------------------------
  IP~3~R1   IP~3~   7.47 ± 0.02           5.39 ± 0.00                               4.66                            2.08 ± 0.02
  IP~3~R1   AdA     8.35 ± 0.03           5.16 ± 0.05                               --                              --
  IP~3~R2   IP~3~   6.82 ± 0.04           4.66 ± 0.07                               4.62                            2.16 ± 0.09[\*](#tf1-2){ref-type="table-fn"}
  IP~3~R3   IP~3~   6.66 ± 0.07           5.55 ± 0.09                               5.34                            1.11 ± 0.08[\*](#tf1-2){ref-type="table-fn"}
  IP~3~R3   AdA     7.71 ± 0.01           5.68 ± 0.04                               --                              --

From experiments similar to those shown in Figures [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}, AdA or IP~3~-evoked Ca^2+^ release and their sensitivity to heparin were used to determine pEC~50~ (as M) and pK~D~ (as g mL^−1^) for DT40 cells expressing IP~3~R1, IP~3~R2 or IP~3~R3. Results are means ± SEM from three independent experiments (six for IP~3~R3).

The affinities for heparin determined from equilibrium-competition binding with ^3^H-IP~3~ to Sf9 membranes expressing IP~3~R1-3 are reproduced from (Nerou *et al*., [@b46]). The batch of heparin used for those binding studies was different from that used for the work reported here. The final column (derived from the results shown in Figures [1](#fig01){ref-type="fig"}B,C and [2](#fig02){ref-type="fig"}A--D) shows paired comparisons of pEC~50~(IP~3~) -- pK~D~(heparin) as a means of reporting the relative effectiveness with which heparin might be expected to block IP~3~-evoked Ca^2+^ release via different IP~3~R subtypes. The results suggest that IP~3~R3 is likely to be substantially more susceptible to inhibition than IP~3~R1 or IP~3~R2.

Denotes a value significantly different from IP~3~R1 in the final column (*P* \< 0.05).

![Heparin is a competitive antagonist with different affinities for types 2 and 3 IP~3~ receptors. (A) Concentration-dependent release of Ca^2+^ by IP~3~ from the intracellular stores of DT40-IP~3~R2 cells in the presence of the indicated concentrations of heparin added 35 s before IP~3~. (B) Schild plot of the results. (C--F) Similar analyses of DT40-IP~3~R3 cells stimulated with IP~3~ (C, D) or AdA (E, F). For D, where maximal attainable concentrations of IP~3~ were insufficient to evoke maximal responses in the presence of the highest concentrations of heparin, the Schild plot shows dose ratios calculated from IP~3~ concentrations that evoked 40% Ca^2+^ release. Results (A--F) are mean ± SEM from three experiments.](bph0171-3298-f2){#fig02}

A similar analysis of the effects of heparin on IP~3~-evoked Ca^2+^ release from permeabilized DT40-IP~3~R2 cells was also consistent with competitive antagonism. The slope of the Schild plots was 0.97 ± 0.06 (*n* = 3) and the K~D~ for heparin was 22 μg·mL^−1^ (pK~D~ = 4.66 ± 0.07) ( Figure [2](#fig02){ref-type="fig"}A and B). IP~3~R3 are less sensitive to IP~3~ than the other subtypes (Iwai *et al*., [@b30]; Saleem *et al*., [@b59]) (Table [1](#tbl1){ref-type="table"}). This made it difficult to add IP~3~ at concentrations sufficient to achieve maximal Ca^2+^ release in the presence of heparin concentrations greater than 5 μg·mL^--1^ (Figure [2](#fig02){ref-type="fig"}C). Assuming the maximal response to IP~3~ was unaffected by heparin, we used the concentrations of IP~3~ that evoked release of 40% of the intracellular stores to construct Schild plots for IP~3~R3. The results were consistent with competitive antagonism. The slope of the Schild plots was 1.14 ± 0.41 (*n* = 3) and the K~D~ for heparin was 2.8 μg·mL^−1^ (pK~D~ = 5.55 ± 0.09) (Figure [2](#fig02){ref-type="fig"}D and Table [1](#tbl1){ref-type="table"}). AdA has ∼10-fold higher affinity than IP~3~ for all three IP~3~R subtypes (Table [1](#tbl1){ref-type="table"}) (Rossi *et al*., [@b56]; Saleem *et al*., [@b59]), and we have shown that the affinity of heparin for IP~3~R1 is similar whether IP~3~ or AdA is used to evoke Ca^2+^ release (Figure [1](#fig01){ref-type="fig"}B--E). To obtain an independent measure of the affinity of IP~3~R3 for heparin, free of the problems associated with using IP~3~, we therefore repeated the Schild analysis using AdA to stimulate Ca^2+^ release. These conditions provided complete concentration--effect relationships for AdA at a wider range of heparin concentrations (Figure [2](#fig02){ref-type="fig"}E). The Schild plots had a slope of 0.98 ± 0.04 (*n* = 6) and the K~D~ for heparin was 2.1 μg·mL^−1^ (pK~D~ = 5.68 ± 0.04) (Figure [2](#fig02){ref-type="fig"}F and Table [1](#tbl1){ref-type="table"}). The affinity of heparin for IP~3~R3 was therefore similar whether measured using IP~3~ or AdA to evoke Ca^2+^ release.

These functional analyses establish that heparin is a competitive antagonist of IP~3~ at all three IP~3~R subtypes, but with different affinities for each (IP~3~R3 \> IP~3~R1 ≥ IP~3~R2) (Table [1](#tbl1){ref-type="table"}). The results are consistent with an analysis of IP~3~ binding to mammalian IP~3~R expressed in Sf9 cells (Nerou *et al*., [@b46]), where the pK~D~ values and rank order of heparin affinity (IP~3~R3 \> IP~3~R1 ∼ IP~3~R2) were similar to those from the present functional analyses (Table [1](#tbl1){ref-type="table"}).

Heparin binding is not solely determined by its interactions with the IP~3~-binding site
----------------------------------------------------------------------------------------

Activation of IP~3~Rs is initiated by binding of IP~3~ to the IP~3~-binding core (IBC, residues 224-604 of IP~3~R1) within the N-terminal region of each IP~3~R subunit (see Introduction) (Seo *et al*., [@b61]). The only contacts between IP~3~ and the IP~3~R are mediated by residues within the IBC (Bosanac *et al*., [@b10]), but interaction of the N-terminal suppressor domain (residues 1-223) with the IBC reduces its affinity for IP~3~. Hence, the IBCs from different IP~3~R subtypes bind IP~3~ with similar affinity, whereas the larger N-terminal regions (NT, residues 1-604) have lower affinities that differ between subtypes. The NTs bind IP~3~ with two- to threefold greater affinities than those of full-length IP~3~Rs, but the NTs and full-length IP~3~Rs have the same rank order of affinities for IP~3~ (NT2 \> NT1 \> NT3) (Iwai *et al*., [@b30]; Rossi *et al*., [@b55]). The results shown in Figure [3](#fig03){ref-type="fig"}A and B, which show IP~3~ binding to bacterially expressed NTs from each of the three IP~3~R subtypes (NT1-3), confirm previous results. Surprisingly, however, equilibrium-competition binding of heparin to NTs in medium that matches that used to measure IP~3~-evoked Ca^2+^ release was not consistent with the results obtained from functional analyses (Figure [3](#fig03){ref-type="fig"}C). The affinity of the NT for heparin was up to 2000-fold greater than that measured in functional analyses, and the rank order of affinity for heparin was different for NTs (NT2 \> NT1 \> \> NT3) and full-length IP~3~Rs (IP~3~R3 \> IP~3~R1 ≥ IP~3~R2) (Nerou *et al*., [@b46]; Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}).

![Heparin binding is not solely determined by its interactions with the IP~3~-binding core. (A) Immunoblots of purified NT1-3 (∼15 μL protein per lane) using an antiserum that recognizes a conserved sequence within all three IP~3~R subtypes (residues 62--75 in rat IP~3~R1). The positions of M~r~ markers (kDa) are shown alongside each blot. (B, C) Equilibrium-competition binding of IP~3~ (B) and heparin (C) to purified NT1-3 in CLM. (D, E) Similar analyses of binding to cerebellar membranes (IP~3~R1). Results (B--E) are means ± SEM from three to six experiments.](bph0171-3298-f3){#fig03}

###### 

Heparin and IP~3~ binding to N-terminal fragments of IP~3~ receptor subtypes

            NT1           NT2           NT3                                            IP~3~R1
  --------- ------------- ------------- ---------------------------------------------- -------------
  IP~3~     7.76 ± 0.07   8.67 ± 0.15   7.39 ± 0.08                                    7.13 ± 0.08
  Heparin   7.42 ± 0.09   7.95 ± 0.32   6.59 ± 0.09[\*](#tf2-1){ref-type="table-fn"}   5.61 ± 0.13

Equilibrium-competition binding with ^3^H-IP~3~ was used to measure pK~D~ values for IP~3~ (as M) and heparin (as g mL^−1^) binding to purified NT1-3 and cerebellar membranes (IP~3~R1). Results are means ± SEM from three to six experiments.

Denotes a significant difference from NT1 (*P* \< 0.05) for .

IP~3~R1 is the major (\>99%) subtype in cerebellar membranes (Wojcikiewicz, [@b78]). Equilibrium-competition binding of heparin to cerebellar membranes in CLM established that the affinity of IP~3~R1 for heparin (pK~D~ = 5.61 ± 0.13, *n* = 3) was similar to that derived from Schild analysis of DT40-IP~3~R1 cells (pK~D~ = 5.39 ± 0.00, *n* = 3) and similar to that reported for heparin binding to IP~3~R1 heterologously expressed in Sf9 cells (Nerou *et al*., [@b46]), but very different to the heparin affinity of NT1 (pK~D~ = 7.42 ± 0.09, *n* = 3) (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). These results demonstrate that the IBC is not the only determinant of competitive heparin binding to IP~3~Rs and suggest either that access of heparin to the IBC is influenced by additional interactions or that heparin binding to an additional site affects IP~3~R gating.

2-APB selectively inhibits Ca^2+^ release via type 1 IP~3~ receptors without affecting IP~3~ binding
----------------------------------------------------------------------------------------------------

2-APB is membrane-permeant and is often used to inhibit IP~3~-evoked Ca^2+^ release (Maruyama *et al*., [@b38]; Missiaen *et al*., [@b43]; Bilmen *et al*., [@b7]), but it has many additional effects. These include modulation of store-operated Ca^2+^ entry (Goto *et al*., [@b23]) and inhibition of the sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase (SERCA) that mediates Ca^2+^ sequestration by the ER (Missiaen *et al*., [@b43]; Bilmen *et al*., [@b7]; Bultynck *et al*., [@b12]). In permeabilized DT40-IP~3~R1 cells, 50 μM 2-APB had no effect on Ca^2+^ uptake by the ER, although higher concentrations reduced the steady-state Ca^2+^ content (Figure [4](#fig04){ref-type="fig"}A and B). This is consistent with high concentrations of 2-APB causing inhibition of SERCA.

![2-APB selectively inhibits Ca^2+^ release via type 1 IP~3~ receptors. (A) Ca^2+^ uptake into the intracellular stores of permeabilized DT40-IP~3~R1 cells is shown after addition of ATP in the presence of the indicated concentrations of 2-APB. Each trace is the average from two wells in a single plate. (B) Summary results show effects of 2-APB on Ca^2+^ contents measured 180 s after addition of ATP. (C--E) Concentration-dependent effects of IP~3~ on Ca^2+^ release from permeabilized DT40-IP~3~R1-3 cells alone or with the indicated concentrations of 2-APB added 35 s before IP~3~. (F) Binding of ^3^H-IP~3~ (1.5 nM) to cerebellar membranes (IP~3~R1), with 3 μM IP~3~ (non-specific) or with 2-APB. Results (B--F) are means ± SEM from three to nine experiments. \**P* \< 0.05, significantly different from control.](bph0171-3298-f4){#fig04}

In permeabilized DT40-IP~3~R1 cells, 2-APB caused a concentration-dependent inhibition of IP~3~-evoked Ca^2+^ release (Figure [4](#fig04){ref-type="fig"}C). With 50 μM 2-APB, the highest concentration that avoids inhibition of Ca^2+^ uptake, there was an approximately sevenfold decrease in IP~3~ sensitivity (ΔpEC~50~ = 0.84 ± 0.12) with no effect on the maximal response to IP~3~ (Figure [4](#fig04){ref-type="fig"}C). The same concentration of 2-APB (50 μM) had no significant effect on IP~3~-evoked Ca^2+^ release from permeabilized DT40-IP~3~R2 or DT40-IP~3~R3 cells (Figure [4](#fig04){ref-type="fig"}D and E). When the 2-APB concentration was increased to 100 μM, which caused some inhibition of Ca^2+^ uptake (Figure [4](#fig04){ref-type="fig"}A and B), there was some inhibition of IP~3~R3, but no effect on IP~3~-evoked Ca^2+^ release via IP~3~R2 (Figure [4](#fig04){ref-type="fig"}D and E; Table [3](#tbl3){ref-type="table"}).

###### 

Selective inhibition of IP~3~ receptor subtypes by common antagonists

                           IP~3~R1                                        IP~3~R2                                   IP~3~R3                                                                                                                                
  ------------------------ ---------------------------------------------- ----------------------------------------- ---------------------------------------------- ---------------------------------------- ---------------------------------------------- --------
  Heparin, 400 μg·mL^−1^   1.88 ± 0.05[\*](#tf3-1){ref-type="table-fn"}   −7 ± 2                                    ND                                             --                                       2.34 ± 0.07[\*](#tf3-1){ref-type="table-fn"}   −3 ± 3
  Heparin, 800 μg·mL^−1^   ND                                             --                                        1.49 ± 0.09[\*](#tf3-1){ref-type="table-fn"}   −4 ± 2                                   ND                                             --
  Caffeine, 70 mM          0.61 ± 0.07[\*](#tf3-1){ref-type="table-fn"}   12 ± 4                                    −0.2 ± 0.07                                    −1 ± 0                                   −0.07 ± 0.08                                   0 ± 5
  2-APB, 50 μM             0.84 ± 0.12[\*](#tf3-1){ref-type="table-fn"}   0 ± 4                                     −0.05 ± 0.10                                   0 ± 4                                    0.02 ± 0.09                                    8 ± 4
  Xestospongin C, 20 μM    0.21 ± 0.10[\*](#tf3-1){ref-type="table-fn"}   6 ± 2[\*](#tf3-1){ref-type="table-fn"}    −0.06 ± 0.04                                   1 ± 1                                    0.12 ± 0.03[\*](#tf3-1){ref-type="table-fn"}   1 ± 2
  Xestospongin D, 20 μM    0.26 ± 0.09[\*](#tf3-1){ref-type="table-fn"}   18 ± 2[\*](#tf3-1){ref-type="table-fn"}   −0.15 ± 0.05                                   8 ± 3[\*](#tf3-1){ref-type="table-fn"}   0.21 ± 0.10[\*](#tf3-1){ref-type="table-fn"}   2 ± 2

Summary of the functional analyses of antagonists on IP~3~-evoked Ca^2+^ release from permeabilized DT40-IP~3~R1-3 cells. The pEC~50~ values for IP~3~ and the maximal Ca^2+^ release are each expressed relative to the response evoked in paired controls without antagonist (Δ = control -- response with antagonist). A positive Δ value demonstrates an inhibition of IP~3~-evoked Ca^2+^ release by the antagonist. The results with Xestospongins C and D are pooled from experiments that included pre-incubation periods of 7 and 12 min (see Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}). Results are means ± SEM from three to nine experiments.

Denotes a value significantly greater than 0 (*P* \< 0.025, one-tailed test).

ND, not determined.

Binding of ^3^H-IP~3~ to IP~3~R1 of cerebellar membranes in CLM was unaffected by 2-APB (Figure [4](#fig04){ref-type="fig"}F) consistent with published results (Maruyama *et al*., [@b38]; Bilmen *et al*., [@b7]). This demonstrates that inhibition of IP~3~R1 by 2-APB is neither due to competition with IP~3~ nor to allosteric inhibition of IP~3~ binding.

Caffeine is a low-affinity antagonist of type 1 IP~3~ receptors
---------------------------------------------------------------

Caffeine is another membrane-permeant antagonist of IP~3~-evoked Ca^2+^ release (Parker and Ivorra, [@b50]; Brown *et al*., [@b11]; Bultynck *et al*., [@b12]; Laude *et al*., [@b35]), but it is effective only at high (mM) concentrations and it has many additional effects (Michelangeli *et al*., [@b41]; Taylor and Tovey, [@b69]). These include stimulation of ryanodine receptors, inhibition of cyclic nucleotide phosphodiesterases, competitive antagonism of adenosine receptors, and effects on the fluorescence of some Ca^2+^ indicators (Brown *et al*., [@b11]; Ehrlich *et al*., [@b18]; Michelangeli *et al*., [@b41]; McKemy *et al*., [@b40]; Taylor and Tovey, [@b69]). High concentrations of caffeine (10--70 mM) inhibited Ca^2+^ release via IP~3~R1 (Figure [5](#fig05){ref-type="fig"}A) without affecting ^3^H-IP~3~ binding to cerebellar membranes (Figure [5](#fig05){ref-type="fig"}D). The latter is consistent with published work (Brown *et al*., [@b11]). The maximal attainable concentration of caffeine (70 mM) caused an approximately fourfold decrease in IP~3~ sensitivity (ΔpEC~50~ = 0.61 ± 0.07) (Figure [5](#fig05){ref-type="fig"}A). Caffeine had no significant effect on IP~3~-evoked Ca^2+^ release via IP~3~R2 or IP~3~R3 (Figure [5](#fig05){ref-type="fig"}B and C; Table [3](#tbl3){ref-type="table"}). At the highest concentration used (70 mM), caffeine significantly reduced the Ca^2+^ content of the intracellular stores, but this inhibition was similar for DT40 cells expressing each of the IP~3~R subtypes (Figure [5](#fig05){ref-type="fig"}E). Inhibition of Ca^2+^ sequestration by the ER is unlikely, therefore, to account for the selective inhibition of IP~3~-evoked Ca^2+^ release via IP~3~R1 (Table [3](#tbl3){ref-type="table"}). These results demonstrate that a high concentration of caffeine modestly, but selectively, inhibits IP~3~-evoked Ca^2+^ release via IP~3~R1 without affecting IP~3~ binding.

![Caffeine is a low-affinity antagonist of type 1 IP~3~R receptors. (A--C) Concentration-dependent effects of IP~3~ on Ca^2+^ release from permeabilized DT40-IP~3~R1-3 cells in the presence of the indicated concentrations of caffeine added 4 min before IP~3~. (D) Binding of ^3^H-IP~3~ (1.5 nM) to cerebellar membranes alone (total), with 3 μM IP~3~ (non-specific) or caffeine. (E) Effect of caffeine added 2 min before ATP on the steady-state Ca^2+^ content of the intracellular stores (percentage of matched control cells) measured 90 s after addition of ATP to DT40-IP~3~R1-3 cells. Results (A--E) are means ± SEM from three experiments. \**P* \< 0.05 significantly different from control.](bph0171-3298-f5){#fig05}

Xestospongins do not effectively inhibit IP~3~-evoked Ca^2+^ release
--------------------------------------------------------------------

Xestospongin C is membrane-permeant and was reported to inhibit IP~3~-evoked Ca^2+^ release from cerebellar microsomes (IC~50~ = 358 nM) without affecting IP~3~ binding (Gafni *et al*., [@b21]). Xestospongin D is less potent. Higher concentrations of Xestospongin C (10--20 μM) were required to inhibit IP~3~-evoked Ca^2+^ release in intact cells. We assessed the effects of Xestospongins C and D from different suppliers (see Materials) on Ca^2+^ release mediated by each of the three IP~3~R subtypes.

Pre-incubation of permeabilized DT40 cells with Xestospongin C (5--20 μM from either source) for 5--12 min before addition of IP~3~ had no significant effect on IP~3~-evoked Ca^2+^ release mediated by any of the three IP~3~R subtypes (Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}). Figure [6](#fig06){ref-type="fig"}A--C show IP~3~-evoked Ca^2+^ release after a 5 min pre-incubation with 5 μM purified Xestospongin C (Gafni *et al*., [@b21]). It had no significant effect on either the response to IP~3~ (Figure [6](#fig06){ref-type="fig"}A--C) or the Ca^2+^ content of the stores (Figure [6](#fig06){ref-type="fig"}D). Pooling all experiments with the highest concentration of Xestospongin C (20 μM, *n* = 6) revealed a statistically significant (*P* \< 0.025, one-tailed test), but very small, inhibition of the maximal response from IP~3~R1, and an even smaller increase in pEC~50~ for IP~3~R1 and IP~3~R3 (Table [3](#tbl3){ref-type="table"} and Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}).

![Xestospongins do not effectively inhibit IP~3~ receptors. (A--C) IP~3~-evoked Ca^2+^ release from permeabilized DT40-IP~3~R1-3 cells is shown with or without 5 μM Xestospongin C (from Gafni *et al*., [@b21]) added 5 min before IP~3~. (D) Effects of Xestospongin C (5--20 μM) added 5--12 min before ATP on the Ca^2+^ content of the intracellular stores (percentages of matched controls without Xestospongin). (E--H) Similar analyses using Xestospongin D (10 μM added 5 min before IP~3~). Results (A--H) are means ± SEM from three experiments.](bph0171-3298-f6){#fig06}

Similar treatments with Xestospongin D (10--20 μM from either source) for 5--12 min caused a modest, but statistically significant (*P* \< 0.025, one-tailed test), inhibition of IP~3~-evoked Ca^2+^ release via IP~3~R1 (Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}). Figure [6](#fig06){ref-type="fig"}E--H show that a 5 min pre-incubation with 10 μM purified Xestospongin D (Gafni *et al*., [@b21]) had no effect on the Ca^2+^ content of the intracellular stores, but modestly inhibited IP~3~-evoked Ca^2+^ release via IP~3~R1 (*P* \< 0.025, one-tailed test, Figure [6](#fig06){ref-type="fig"}E). Pooling results with the highest concentration of Xestospongin D (20 μM, *n* = 6) revealed a statistically significant (*P* \< 0.025, one-tailed test), but very small, inhibition of the maximal response from IP~3~R1 and IP~3~R2, and a tiny increase in the pEC~50~ for IP~3~R1 and IP~3~R3 (Table [3](#tbl3){ref-type="table"} and Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}). These small inhibitory effects of Xestospongins C and D are not sufficient to be useful, and nor are they sufficient to reliably assess whether there is any subtype-selective interaction of Xestospongins with IP~3~Rs.

We also assessed the effects of Xestospongins on IP~3~-evoked Ca^2+^ release from intact and permeabilized HEK cells. IP~3~ caused a concentration-dependent release of Ca^2+^ from the intracellular stores of permeabilized HEK cells (Figure [7](#fig07){ref-type="fig"}A and B). Pre-incubation of the permeabilized cells for 5 min with Xestospongin C (5 μM) or Xestospongin D (10 μM) had no effect on the Ca^2+^ content of the intracellular stores (Figure [7](#fig07){ref-type="fig"}C) or the Ca^2+^ release evoked by IP~3~ (Figure [7](#fig07){ref-type="fig"}A and B). Carbachol, via endogenous M~3~ muscarinic receptors of HEK cells, stimulates PLC and thereby IP~3~-evoked Ca^2+^ release. Preincubation of HEK cells with Xestospongin C or D (10 μM) for 30 min had no significant effect on the Ca^2+^ signals evoked by any concentration of carbachol (Figure [7](#fig07){ref-type="fig"}D). This conflicts with published results from similar experiments, where Xestospongin C (10 μM for 30 min) caused substantial, though incomplete, inhibition of carbachol-evoked Ca^2+^ signals (Kurian *et al*., [@b34]). It is, however noteworthy, in light of evidence that Xestospongins have been reported to inhibit Ca^2+^ uptake into the ER (Castonguay and Robitaille, [@b13]; Solovyova *et al*., [@b63]), that in the experiments from Kurian *et al*. HEK cells were incubated with Xestospongin for 30 min in Ca^2+^-free medium, while in our experiments extracellular free Ca^2+^ was removed immediately before stimulation with carbachol. The discrepant results may, therefore, reflect an increased loss of Ca^2+^ from intracellular stores during prolonged exposure to Xestospongin in Ca^2+^-free medium.

![Xestospongins do not inhibit IP~3~-evoked Ca^2+^ signals in HEK cells. (A--C) Permeabilized HEK cells were incubated with Xestospongin C (5 μM) or Xestospongin D (10 μM) for 5 min before addition of IP~3~. Both Xestospongins were prepared as described (Gafni *et al*., [@b21]). Results show IP~3~-evoked Ca^2+^ release (A, B) or the steady-state Ca^2+^ content of the intracellular stores (C, as a percentage of matched controls without Xestospongin). (D) Concentration-dependent effects of carbachol on the increase in intracellular free Ca^2+^ concentration \[Ca^2+^\]~i~ of intact fluo-4-loaded HEK cells after treatment with Xestospongins C or D (10 μM for 30 min). pEC~50~ (M) values for the carbachol-evoked Ca^2+^ signals were 4.99 ± 0.13, 4.92 ± 0.23 and 4.70 ± 0.11 for control cells and cells treated with Xestospongins C and D respectively. Results (A--D) are means ± SEM. from three experiments.](bph0171-3298-f7){#fig07}

Discussion
==========

Acute analyses of IP~3~-evoked Ca^2+^ signalling are handicapped by lack of effective and selective antagonists (Michelangeli *et al*., [@b41]; Bultynck *et al*., [@b12]). Furthermore, the subtype-selectivity and in many cases the mechanism of action of the antagonists that are routinely used are not known. We have addressed these issues by examining the functional effects of the most widely used antagonists of IP~3~R in cells expressing only a single IP~3~R subtype.

Heparin is a competitive antagonist of IP~3~ at cerebellar IP~3~Rs (Ghosh *et al*., [@b22]), most likely because as a polyanion it may partially mimic the phosphate groups of IP~3~. That is consistent with evidence that other polyanions, like decavanadate, ATP and dextran sulphate, can also competitively inhibit IP~3~Rs (Bultynck *et al*., [@b12]). Our functional analyses establish that heparin is a competitive antagonist of all three IP~3~R subtypes, but with modestly different affinities for each (IP~3~R3 \> IP~3~R1 ≥ IP~3~R2) (Figures [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}; Table [1](#tbl1){ref-type="table"}). The affinities of IP~3~R subtypes for heparin derived from functional analyses were similar to those determined from equilibrium-competition binding to native IP~3~R1 (Figure [3](#fig03){ref-type="fig"}E) or to heterologously expressed IP~3~R subtypes (Table [1](#tbl1){ref-type="table"}). However, heparin bound to N-terminal fragments (NT) of IP~3~Rs that include the IBC with an affinity that was up to 2000-fold greater than its affinity for the corresponding full-length IP~3~R (Tables [1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}). Furthermore, the rank order of heparin affinity for IP~3~R1-3 and NT1-3 was different. We conclude that heparin inhibits IP~3~-evoked Ca^2+^ release by competing with IP~3~, but its access to the IBC is substantially impaired in full-length IP~3~Rs within native membranes. Phospholipids may contribute to the substantially lesser affinity of heparin for IP~3~R in native membranes by electrostatically repelling the approach of polyanionic heparin to the membrane-bound IBC. In addition, we suggest that charged residues on the IP~3~R surface may differentially influence heparin access to the IBC of each IP~3~R subtype and thereby contribute to the modestly different affinities of heparin for IP~3~R subtypes (Table [1](#tbl1){ref-type="table"}). Our observations have more general significance for analyses of competitive antagonism. We have demonstrated that properties of either the receptor or its environment that are remote from the ligand-binding site may significantly affect the apparent affinity of a receptor for a competitive antagonist.

Because heparin is a competitive antagonist of IP~3~ (Figures [1](#fig01){ref-type="fig"} and [2](#fig02){ref-type="fig"}), its experimental utility will depend on its affinity relative to IP~3~ for each IP~3~R subtype. Table [1](#tbl1){ref-type="table"} addresses this issue by comparing measured affinities for heparin with EC~50~ values for IP~3~ as an estimate of the relative affinity of each IP~3~R subtype for IP~3~. The analysis indicates that within native cells, responses of IP~3~R3 to IP~3~ are likely to be more susceptible to inhibition by heparin than the responses mediated by other IP~3~R subtypes.

Both 2-APB and caffeine selectively inhibited IP~3~-evoked Ca^2+^ release via IP~3~R1, without affecting IP~3~ binding (Figures [4](#fig04){ref-type="fig"} and [5](#fig05){ref-type="fig"}; Table [3](#tbl3){ref-type="table"}). Higher concentrations of 2-APB caused some inhibition of IP~3~R3, but this was accompanied by inhibition of ER Ca^2+^ uptake (Figure [4](#fig04){ref-type="fig"}). The highest concentration of caffeine used (70 mM) also inhibited Ca^2+^ sequestration by the ER, but without significantly affecting the sensitivity to IP~3~ of IP~3~R2 or IP~3~R3, or the fraction of the remaining Ca^2+^ stores released via them by a maximally effective concentration of IP~3~ (Figure [5](#fig05){ref-type="fig"}). Previous analyses of cells expressing different mixtures of native IP~3~R subtypes have also suggested that IP~3~R2 may be resistant to inhibition by 2-APB (Gregory *et al*., [@b25]; Hauser *et al*., [@b28]; Kukkonen *et al*., [@b33]; Bootman *et al*., [@b9]; Soulsby and Wojcikiewicz, [@b64]) and caffeine (Kang *et al*., [@b31]). The mechanism of action of 2-APB is unresolved, but for IP~3~R1 caffeine appears to compete with ATP for the site through which ATP potentiates IP~3~-evoked Ca^2+^ release (Missiaen *et al*., [@b42]; Maes *et al*., [@b36]). This mechanism appears not to explain the actions of 2-APB (Missiaen *et al*., [@b43]). ATP potentiates IP~3~-evoked Ca^2+^ release via all three IP~3~R subtypes (Smith *et al*., [@b62]; Mak *et al*., [@b37]; Maes *et al*., [@b36]; Tu *et al*., [@b74]; Betzenhauser *et al*., [@b5]), but the mechanisms and ATP-binding sites differ (Betzenhauser *et al*., [@b5]; [@b6]; Betzenhauser and Yule, [@b4]). Work from Yule and his colleagues suggests that IP~3~R2 is most sensitive to ATP and for it, but not other IP~3~R subtypes, an ATPB site within each IP~3~R subunit mediates the potentiating effect of ATP (Betzenhauser and Yule, [@b4]). It is, therefore, tempting to speculate that the different sensitivities of IP~3~R subtypes to inhibition by caffeine (Figure [5](#fig05){ref-type="fig"}) may be related to their different modes of regulation by ATP.

Xestospongins were initially shown to inhibit IP~3~-evoked Ca^2+^ release selectively (Gafni *et al*., [@b21]), and numerous subsequent analyses of their effects on intact cells are consistent with inhibition of IP~3~Rs (e.g. Bishara *et al*., [@b8]; Duncan *et al*., [@b17]; Oka *et al*., [@b47]; Ozaki *et al*., [@b48]; Rosado and Sage, [@b53]; Schafer *et al*., [@b60]; Yuan *et al*., [@b80]), but few of these later analyses directly addressed the effects of Xestospongins on IP~3~Rs (e.g. Oka *et al*., [@b47]; Ozaki *et al*., [@b48]). The latter is important because Xestospongins have additional effects that include inhibition of SERCA (De Smet *et al*., [@b16]; Castonguay and Robitaille, [@b13]; Solovyova *et al*., [@b63]), store-operated Ca^2+^ entry (Bishara *et al*., [@b8]), L-type Ca^2+^ channels and Ca^2+^-activated K^+^ channels (Ozaki *et al*., [@b48]), and modulation of ryanodine receptors (Ta *et al*., [@b68]). The potencies of Xestospongins also differ between studies and some reports challenge whether they effectively inhibit IP~3~Rs (Solovyova *et al*., [@b63]; Duncan *et al*., [@b17]; Govindan and Taylor, [@b24]). We used two sources of Xestospongins C and D, a range of concentrations and incubation periods, two different cell types (see also Govindan and Taylor, [@b24]), and both intact and permeabilized cells. Although the Xestospongins caused some inhibition of IP~3~-evoked Ca^2+^ release, none of our analyses succeeded in demonstrating that attainable (≤20 μM) concentrations of Xestospongins substantially inhibited any IP~3~R subtype (Figures [6](#fig06){ref-type="fig"} and [7](#fig07){ref-type="fig"}; Table [3](#tbl3){ref-type="table"}; Supporting Information [Table S1](#SD1){ref-type="supplementary-material"}).

We conclude that none of the commonly used antagonists of IP~3~Rs is free of pitfalls. Heparin is perhaps the most reliable, it is competitive with IP~3~, but it is membrane-impermeant, and its binding to the IBC of IP~3~Rs is influenced by more distant residues that cause it to bind with different affinity to each IP~3~R subtype (Figures [3](#fig03){ref-type="fig"}). Caffeine and 2-APB are membrane-permeant, they do not compete with IP~3~, but neither achieves effective inhibition of IP~3~Rs without affecting other Ca^2+^-regulating proteins, and both show selectivity for IP~3~R1 (Figures [4](#fig04){ref-type="fig"} and [5](#fig05){ref-type="fig"}). Xestospongins are membrane-permeant and reported to inhibit IP~3~-evoked Ca^2+^ release without affecting IP~3~ binding (Gafni *et al*., [@b21]), but in our hands they do not inhibit any IP~3~R subtype (Figures [6](#fig06){ref-type="fig"} and [7](#fig07){ref-type="fig"}).
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2-APB

:   2-aminoethoxydiphenyl borate

AdA

:   adenophostin A

CLM

:   cytosol-like medium

CPA

:   cyclopiazonic acid

ER

:   endoplasmic reticulum

HBS

:   HEPES-buffered saline

IBC

:   IP~3~-binding core (residues 224-604)

IP~3~

:   inositol 1,4,5-trisphosphate

IPTG

:   isobutyl-β-D-thiogalactoside

NT1-3

:   residues 1-604 of IP~3~R1-3

SERCA

:   sarcoplasmic/endoplasmic reticulum Ca^2+^-ATPase

TEM

:   Tris-EDTA medium

Supporting information
======================

Additional Supporting Information may be found in the online version of this article at the publisher\'s web-site:

<http://dx.doi.org/10.1111/bph.12685>

###### 

**Table S1** Xestospongins ineffectively inhibit IP~3~-evoked Ca^2+^ release.
